HOME >> BIOLOGY >> NEWS
Herceptin plus chemotherapy significantly increases disease-free survival in breast cancer

Combining the molecularly targeted therapy Herceptin with chemotherapy in women with early stage breast cancer significantly improves disease-free survival for patients with a specific genetic mutation that results in very aggressive disease, a top UCLA researcher reported Thursday.

Dr. Dennis Slamon, whose laboratory and clinical research lead to the development of Herceptin, reported results of the Phase III study of more than 3,200 women Thursday at the 29th annual San Antonio Breast Cancer Symposium.

The three-armed study compared the standard therapy of Adriamycin and Carboplatin followed by Taxotere (ACT), an experimental regimen of Adriamycin and Carboplatin followed by Taxotere and one year of Herceptin (ACTH), and an experimental regimen of Taxotere and Carboplatin with one year of Herceptin (TCH).

The study tested Herceptin with and without Adriamycin, an anthracycline commonly used to treat breast cancer but one that, when paired with Herceptin, can cause permanent heart damage. Researchers wanted to determine whether they could provide a therapy as effective as ACTH without the resulting cardiac problems. The study, Slamon said, showed that the women who did not receive Adriamycin did just as well as those who did, and they experienced a five-fold decrease in significant heart toxicities compared to those who got Adriamycin. Also, some women in the ACTH arm developed leukemias, while none of the women on the non-Adriamycin arm did, Slamon said.

"This study demonstrates unequivocally that the best treatment for early stage HER-2 positive breast cancer is obtained with a non-anthracycline regimen, TCH, that avoids the significant cardiac damage found when Adriamycin is used with Herceptin," said Slamon, director of clinical/translational research at UCLAs Jonsson Cancer Center. "This trial should impact the way early stage breast cancer is treated, with TCH being considered the preferred option."

H
'"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
14-Dec-2006


Page: 1 2

Related biology news :

1. Gene profiling predicts resistance to breast cancer drug Herceptin
2. Herceptin plus chemotherapy improves disease-free survival in early breast cancer
3. Nanoparticles carry chemotherapy drug deeper into solid tumors
4. A faster way to recover from chemotherapy and marrow transplant
5. PET accurately identifies esophageal cancer patients positive responses to chemotherapy
6. Combining NSAIDs with chemotherapy, radiation may improve cancer treatment
7. FDG-PET imaging clearly predicts lung cancer patients response to chemotherapy
8. Gene analysis might explain ethnic differences in sensitivity to chemotherapy in lung cancer
9. Enhancing chemotherapys efficacy: New agent has synergistic effect with standard drugs
10. Massive gene screening points way to more effective chemotherapy
11. Researchers find the mechanism by which cells resist chemotherapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/25/2020)... ... May 22, 2020 , ... Oxford Nanopore Technologies is in advanced development of ... that causes COVID-19. , The LamPORE assay is designed to be rapid, ... very large numbers of samples. Hardware and reagents sit outside current, squeezed supply ...
(Date:5/21/2020)... ... 2020 , ... Catalent, the leading global provider of advanced ... and consumer health products, today announced that Jean-François Chaubard, Senior Director, Open Innovation ... Paris Virtual conference, which takes place on 28 – 29 May, 2020. , ...
(Date:5/15/2020)... ... May 15, 2020 , ... The National Institutes of Health (NIH) has ... in Frederick, Maryland and Tysons Corner, Virginia, to provide patent legal services under two ... in the field of chemistry. The firm is one of nine firms in the ...
Breaking Biology News(10 mins):
(Date:5/5/2020)... ... May 05, 2020 , ... ... today the launch of its iGlucose® LTE Cat-M Cellular Connected Diabetes ... LTE Cat-M1 technology, the industry’s newest and broadest cellular connectivity available, to provide ...
(Date:4/22/2020)... , ... April 20, 2020 , ... ... in Cambridge, MA, announced today that Omixon’s founder and chairman Dr. Attila Berces ... Omixon’s flagship product Holotype HLA since 2014 before stepping into the CEO role ...
(Date:4/7/2020)... ... 06, 2020 , ... Gateway Genomics , leading developer of direct-to-consumer genetic ... Gender DNA Tests sold in March, just months after attaining the 150,000-test landmark ... where a mom could order her kit online, collect a DNA sample from her ...
(Date:4/1/2020)... ... March 31, 2020 , ... ... has developed a method using its revolutionary NEXTGENPCR endpoint thermocycler and consumables ... smaller reaction volumes, increased samples per run, and standard, affordable laboratory equipment, ...
Breaking Biology Technology:
Cached News: